MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients by Guilin Wang, Chen Miao, Lijun Mo, Ulf D. Kahlert, Jinfeng Wu, Minglin Ou, Renxiang Huang, Ruifa Feng, Weiyi Pang, Wenjie Shi, Wenjie Shi

Get full text

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States by Fan Yang, Chloe Shay, Marin Abousaud, Chris Tang, Yamin Li, Zhaohui Qin, Nabil F. Saba, Yong Teng

“…‘Respiratory, thoracic, mediastinal diseases’ and ‘reproductive system and breast diseases’ were the main types of disorders associated with treatment with these ICIs in male and female patients, respectively. …”
Get full text

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. by John R Hawse, Malayannan Subramaniam, Muzaffer Cicek, Xianglin Wu, Anne Gingery, Sarah B Grygo, Zhifu Sun, Kevin S Pitel, Wilma L Lingle, Matthew P Goetz, James N Ingle, Thomas C Spelsberg

“…Taken together, these data demonstrate that endoxifen's mechanism of action is different from that of 4HT and ICI and provide mechanistic insight into the potential importance of endoxifen in the suppression of breast cancer growth and progression.…”
Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy by Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao

“…Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. …”
Get full text

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors by Jennifer K. Matsui, Haley K. Perlow, Rohit K. Raj, Ansel P. Nalin, Eric J. Lehrer, Rupesh Kotecha, Daniel M. Trifiletti, Shearwood McClelland, Kari Kendra, Nicole Williams, Dwight H. Owen, Carolyn J. Presley, Evan M. Thomas, Sasha J. Beyer, Dukagjin M. Blakaj, Manmeet S. Ahluwalia, Raju R. Raval, Joshua D. Palmer

“…Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. …”
Get full text

Increasing cure rates of solid tumors by immune checkpoint inhibitors by Weijie Ma, Ruobing Xue, Zheng Zhu, Hizra Farrukh, Wenru Song, Tianhong Li, Lei Zheng, Chong-xian Pan

“…The promising results of these trials have led to the United States Food and Drug Administration (FDA) approvals of ICIs as neoadjuvant or adjuvant therapies for non-small cell lung cancer, melanoma, triple-negative breast cancer, and bladder cancer, and the list continues to grow. …”
Get full text

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors by Florent Peyraud, Antoine Italiano

“…Although major breakthroughs have been performed with either PARPi or ICIs alone in multiple cancers, primary or acquired resistance often leads to tumor escape. …”
Get full text

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments by Ping Liao, Mengmeng Jiang, Md Sahidul Islam, Yiru Wang, Xin Chen, Xin Chen, Xin Chen, Xin Chen

“…Immune checkpoint inhibitors (ICIs) by targeting PD-1/PD-L1 or CTLA-4 have markedly improved the outcome of cancer patients. …”
Get full text

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors by Ximing Yang, Miaozhi Gao, Runshi Xu, Yangyang Tao, Wang Luo, Binya Wang, Wenliang Zhong, Wenliang Zhong, Lan He, Lan He, Yingchun He, Yingchun He, Yingchun He

“…A more effective and comprehensive treatment strategy using a combination of hyperthermia and immune checkpoint inhibitor (ICI) therapies has gained attention. This paper summarizes the relevant preclinical and clinical studies on hyperthermia combined with ICI therapies and compares the efficacy of two types of hyperthermia combined with ICIs, in order to provide a better treatment for the recurrence and metastasis of clinically malignant tumors.…”
Get full text

Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression by Khan O. Mohammad, Hanna Fanous, Sneha Vakamudi, Yan Liu

“…Abstract Background Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. …”
Get full text

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report by Camille M. Powers, Hannah Verma, Jeremy Orloff, Austin J. Piontkowski, Amy Tiersten, Angela Lamb, Nicholas Gulati

“…AbstractIn this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event (cirAE) secondary to an immune checkpoint inhibitor (ICI), pembrolizumab. …”
Get full text

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis by Yu Feng, Yunxia Tao, Haizhu Chen, Yu Zhou, Le Tang, Chenwei Liu, Xingsheng Hu, Yuankai Shi

Get full text

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case by Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, Yinglai Huang

Get full text

Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers by Ina Shehaj, Maria Schröder, Valerie Catherine Linz, Slavomir Krajnak, Katrin Almstedt, Kathrin Stewen, Roxana Schwab, Annette Hasenburg, Marcus Schmidt, Anne-Sophie Heimes

“…Methods: In the present retrospective overview, we evaluated patients with gynecologic malignancies (breast, endometrial, cervical, ovarian) who received ICIs with regard to the incidence, type, and time to onset of irAEs. …”
Get full text

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events by Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors

Get full text

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021 by Hongyi Zhang, Hongyi Zhang, Yanlong Shi, Jianghui Ying, Yi Chen, Rong Guo, Xin Zhao, Lingling Jia, Jiachao Xiong, Fei Jiang

Get full text

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy by Ming Yi, Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Zhenyu Zhao, Kongming Wu

Get full text

Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review by Sara Mucherino, Valentina Lorenzoni, Isotta Triulzi, Marzia Del Re, Valentina Orlando, Annalisa Capuano, Romano Danesi, Giuseppe Turchetti, Enrica Menditto

“…Overall, the review highlights a certain degree of uncertainty about the cost-effectiveness of ICI. In particular, we found PD-L1 expression associated with ICI treatment to be a cost-effective strategy, particularly in NSCLC, urothelial, and renal cell carcinoma. …”
Get full text

Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment by Zhang Y, Han X, Wang K, Liu D, Ding X, Hu Z, Wang J

“…It is therefore essential that alternative strategies are developed to improve the therapeutic outcomes of ICI in non-responsive TNBC cases. The efficacy of pH-responsive nanomicelles (P/A/B@NM) co-loaded with paclitaxel (PTX), CXCR4 antagonist AMD3100, and PD-1/PD-L1 inhibitor BMS-1 activating the T cell-mediated antitumor immune response were evaluated using a 4T1 antiPD-1-resistance breast tumor model.Methods: In vitro, pH-responsive antitumor effect of P/A/B@NM was investigated by assessing cell viability, migration and invasion. …”
Get full text

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer by Shin-Yi Chung, Yu-Chan Chang, Dennis Shin-Shian Hsu, Ya-Chi Hung, Meng-Lun Lu, Yi-Ping Hung, Nai-Jung Chiang, Chun-Nan Yeh, Michael Hsiao, John Soong, Yeu Su, Ming-Huang Chen

“…Purpose: Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy can improve the limited efficacy of colorectal cancer (CRC) immunotherapy. …”
Get full text